Louvain Drug Research Institute, Louvain Centre for Toxicology and Applied Pharmacology, LDRI/PKDM B1.73.13, Av. E. Mounier 73, 1200 Bruxelles, Belgique.
J Clin Pharmacol. 2012 Dec;52(12):1833-43. doi: 10.1177/0091270011423661. Epub 2011 Dec 29.
Mycophenolic acid (MPA) and tacrolimus (TAC) are immunosuppressive agents used in combination with corticosteroids for the prevention of acute rejection after solid organ transplantation. Their pharmacokinetics (PK) show considerable unexplained intraindividual and interindividual variability, particularly in the early period after transplantation. The main objective of the present work was to design a study based on D-optimality to describe the PK of the 2 drugs with good precision and accuracy and to explain their variability by means of patients' demographics, biochemical test results, and physiological characteristics. Pharmacokinetic profiles of MPA and TAC were obtained from 65 stable adult renal allograft recipients on a single occasion (ie, day 15 after transplantation). A sampling schedule was estimated based on the D-optimality criterion with the POPED software, using parameter values from previously published studies on MPA and TAC modeling early after transplantation. Subsequently, a population PK model describing MPA and TAC concentrations was developed using nonlinear mixed-effects modeling. Optimal blood-sampling times for determination of MPA and TAC concentrations were estimated to be at 0 (predose) and at 0.24, 0.64, 0.98, 1.37, 2.38, and 11 hours after oral intake of mycophenolate and TAC. The PK of MPA and TAC were best described by a 2-compartment model with first-order elimination. For MPA, the absorption was best described by a transit compartment model, whereas first-order absorption with a lag time best described TAC transfer from the gastrointestinal tract. Parameters were estimated with good precision and accuracy. While hematocrit levels and CYP3A5 genetic polymorphism significantly influenced TAC clearance, the pharmaceutical formulation and MRP2 genetic polymorphism were retained as significant covariates on MPA absorption and elimination, respectively. The prospective use of the simultaneous D-optimal design approach for MPA and TAC has allowed good estimation of MPA and TAC PK parameters in the early period after transplantation characterized by a very high unexplained variability. The influence of some relevant covariates could be shown.
霉酚酸(MPA)和他克莫司(TAC)是免疫抑制剂,与皮质类固醇联合用于预防实体器官移植后的急性排斥反应。它们的药代动力学(PK)表现出相当大的个体内和个体间不可解释的变异性,特别是在移植后早期。本工作的主要目的是设计一项基于 D 最优性的研究,以描述 2 种药物的 PK,具有良好的精度和准确性,并通过患者的人口统计学、生化测试结果和生理特征来解释其变异性。在单次(即移植后 15 天)时,从 65 名稳定的成年肾移植受者中获得了 MPA 和 TAC 的 PK 谱。根据 D 最优性标准,使用先前发表的关于 MPA 和 TAC 建模的研究中的参数值,使用 POPED 软件估算了采样方案。随后,使用非线性混合效应建模方法,开发了一个描述 MPA 和 TAC 浓度的群体 PK 模型。估计最佳血样时间用于确定 MPA 和 TAC 浓度为 0(预剂量)和口服麦考酚酯和 TAC 后 0.24、0.64、0.98、1.37、2.38 和 11 小时。MPA 和 TAC 的 PK 最好由具有一级消除的 2 隔室模型描述。对于 MPA,吸收最好由转运隔室模型描述,而具有滞后时间的一级吸收最好描述 TAC 从胃肠道的转移。参数估计具有良好的精度和准确性。虽然红细胞压积水平和 CYP3A5 遗传多态性显著影响 TAC 清除率,但药物制剂和 MRP2 遗传多态性分别作为 MPA 吸收和消除的显著协变量保留。前瞻性使用 MPA 和 TAC 的同时 D 最优设计方法允许在移植后早期非常高的未解释变异性下良好地估计 MPA 和 TAC PK 参数。可以显示一些相关协变量的影响。